San Diego, CA, United States of America

Indrawan James McAlpine

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 7.6

ph-index = 4

Forward Citations = 154(Granted Patents)


Company Filing History:


Years Active: 2006-2025

Loading Chart...
Loading Chart...
14 patents (USPTO):

Title: Unveiling the Inventive Journey of Indrawan James McAlpine

Introduction:

Indrawan James McAlpine, a talented inventor based in San Diego, CA, has made significant contributions to the field of pharmaceuticals with his innovative patents and groundbreaking research. With a total of 13 patents to his name, McAlpine's work has advanced the realms of medicine and cancer treatment.

Latest Patents:

McAlpine's latest patents include Cyclopentane-based modulators of STING (Stimulator of Interferon Genes) and Substituted Carbonucleoside Derivatives useful as anticancer agents. These patents showcase his expertise in developing compounds with vast therapeutic potential, paving the way for novel treatments in disease management.

Career Highlights:

Throughout his career, Indrawan James McAlpine has worked with renowned companies such as Pfizer Corporation and Iteos Therapeutics. His tenure at these esteemed organizations has provided him with valuable experience and resources to further his research in pharmaceuticals.

Collaborations:

McAlpine's collaborative spirit is evident through his professional relationships with coworkers Martin James Wythes and Eugene Yuanjin Rui. Together, they have synergized their expertise to drive innovation and push the boundaries of scientific discovery in the field of medicine.

Conclusion:

In conclusion, Indrawan James McAlpine's journey as an inventor is characterized by his unwavering dedication to scientific excellence and the pursuit of cutting-edge solutions in pharmaceutical research. His patents stand as a testament to his ingenuity and commitment to making a positive impact on healthcare and cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…